Finding advanced depression treatment closer to home
Rockland County residents with treatment-resistant depression now have access to specialized ketamine therapy and Spravato treatments without the 60–90-minute commute to Manhattan. Nushama operates a fully equipped clinic in New City at 200 E. Eckerson Road, offering board-certified medical supervision, preparation and integration support (the process of translating insights from treatment into lasting behavioral change), and both IV ketamine (intravenous racemic ketamine infusions) and FDA-approved Spravato (esketamine nasal spray) under one roof. This means residents of Spring Valley, Nyack, Suffern, Pearl River, and surrounding communities can receive the same clinical excellence found in top Manhattan practices—without the added stress of long-distance travel.
The difference is tangible: no more navigating rush-hour traffic across the Tappan Zee Bridge, no need to coordinate childcare for distant appointments, and no exhaustion from multi-hour round trips while managing severe depression symptoms. Local access means consistent, sustainable care that fits into your life rather than disrupting it.
Proximity matters deeply for healing. Rockland County health data identifies depression and substance use as top concerns among the county’s 348,000 residents. When treatment requires weekly or twice-weekly visits during the acute phase, travel stress can compound treatment resistance and make follow-through significantly harder. Integration benefits from continuity and community connection, both of which become more challenging when your provider is an hour away in another county.
Why traditional antidepressants may not be working
Traditional antidepressants primarily target serotonin reuptake, addressing only one neurochemical pathway involved in depression—leaving many people without meaningful relief. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) work by increasing the availability of these neurotransmitters in the brain, but this mechanism does not produce remission for everyone. Antidepressants do not achieve remission in 30–55% of people who try them, depending on how strictly remission is defined. Research in Dialogues in Clinical Neuroscience shows that treatment-resistant depression affects roughly one-third of people in clinical trials, though real-world prevalence ranges even higher when accounting for partial response or residual symptoms.
Treatment-resistant depression is typically defined as trying two or more antidepressants at adequate doses and durations without meaningful relief. This might mean taking Prozac for twelve weeks, then switching to Zoloft for another twelve, then adding Wellbutrin or a mood stabilizer—only to find that the heaviness, numbness, or pervasive hopelessness remains. The prevalence of treatment-resistant depression reaches up to one-third of people, and many more experience only partial improvement that leaves them functioning but far from well.
The limitation of SSRIs lies in their narrow target. Depression involves disrupted circuits across multiple neurotransmitter systems—serotonin, yes, but also glutamate, GABA, dopamine, and inflammatory pathways. SSRIs address only serotonin reuptake, and even when they work, benefits typically take 4–8 weeks to emerge. During that waiting period, symptoms persist, and many people experience side effects that limit adherence: weight gain, sexual dysfunction, emotional blunting, sleep disturbances, or gastrointestinal discomfort.
Ketamine works through an entirely different mechanism. It acts primarily on the glutamate system and N-methyl-D-aspartate (NMDA) receptors, not serotonin, triggering a cascade of changes that can reduce symptoms within hours to days rather than weeks. Research on rapid synapse formation shows that ketamine promotes strengthened neural connections through pathways involving brain-derived neurotrophic factor (BDNF) and mammalian target of rapamycin (mTOR). This process leverages neuroplasticity—the brain’s ability to form new synapses and pathways—creating opportunities for emotional and behavioral shifts that traditional antidepressants may not access.
Nushama’s comprehensive psychiatric evaluation during intake ensures members meet clinical criteria for treatment-resistant depression before beginning ketamine therapy in Rockland County . The team reviews your medication history, symptom timeline, and contraindications to determine whether IV ketamine or Spravato is the right next step.
Comparing IV ketamine and Spravato options in Rockland
IV ketamine delivers 100% bioavailability (the full dose enters the bloodstream) and may facilitate deeper experiential processing, while Spravato (esketamine nasal spray) offers FDA approval for treatment-resistant depression and is covered by many insurance plans. Nushama offers both modalities at the New City clinic, allowing the medical team to tailor the protocol to your specific clinical needs, insurance coverage, and treatment goals.
IV ketamine—also called racemic ketamine—is administered intravenously over a 40–60-minute infusion. Because the medication is delivered directly into the bloodstream, 100% of the dose reaches the brain, allowing for precise titration and consistent effects. IV ketamine has a longer history of off-label use for depression, dating back to early 2000s research at institutions like Yale and Mount Sinai. The acute treatment series typically consists of six infusions over 2–3 weeks, with maintenance infusions scheduled as needed. This option is typically not covered by insurance, and the initial series costs approximately $4,800. Some members report that the intravenous route facilitates deeper dissociative experiences (temporary sensations of detachment from one’s body or surroundings) and psychedelic phenomena that contribute to therapeutic insight.
Spravato (esketamine) is the S-enantiomer of ketamine, delivered via nasal spray under direct medical supervision. It received FDA approval specifically for treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior. The protocol begins with two sessions per week for four weeks, then transitions to weekly or biweekly maintenance sessions. Because Spravato is FDA-approved, it is covered by many major insurance plans, including Oxford, UnitedHealthcare, Cigna, Aetna, and Humana—making it more financially accessible for many members. The dissociative intensity is generally lower compared to IV ketamine, which some people prefer and others find less therapeutically potent.
The decision between IV ketamine and Spravato is made collaboratively during the initial psychiatric evaluation. The physician assesses symptom severity, prior treatment history, contraindications (such as uncontrolled hypertension or active psychosis), and practical considerations like insurance status and financial capacity. Some members begin with Spravato to take advantage of insurance coverage, then transition to IV ketamine if they seek deeper experiential work.
For a detailed breakdown of efficacy and logistics, see Spravato vs. IV ketamine . Nushama also offers transparent pricing and financing options to support accessibility, including payment plans and scholarships.
The importance of medical supervision and safety
Ketamine temporarily alters consciousness—making rigorous medical oversight essential for safe, effective treatment. At-home or telemedicine ketamine services lack the real-time monitoring needed to manage cardiovascular effects, dissociative episodes, or emergency situations that can arise during treatment sessions.
Ketamine can elevate blood pressure and heart rate, sometimes significantly, especially during the first 30 minutes of infusion. For people with pre-existing cardiovascular conditions, this can pose serious risks if not monitored and managed immediately. Dissociation may be disorienting, frightening, or deeply uncomfortable without skilled guidance present in the room. The FDA has issued warnings about compounded ketamine from telemedicine platforms, citing risks of abuse, psychiatric events, respiratory depression, and the absence of adequate safety protocols.
Nushama’s safety protocols in New City reflect the same rigorous standards used in hospital-based ketamine programs. Board-certified physicians with specialized training in ketamine administration oversee every treatment from start to finish. Registered nurses and integration coaches monitor members every 10 minutes during infusions, tracking vital signs—heart rate, blood pressure, oxygen saturation, and respiratory rate—and assessing mental status. The team is ACLS-certified (Advanced Cardiovascular Life Support) and equipped to respond to medical emergencies, including allergic reactions, cardiovascular events, or severe dissociative distress.
Comprehensive medical screening occurs before any treatment begins. The intake process rules out contraindications such as uncontrolled hypertension, active psychosis, pregnancy, unstable cardiac conditions, or a history of substance use disorder that would make ketamine unsafe. Private treatment suites are designed for comfort, grounding, and security—low lighting, comfortable recliners, noise-canceling headphones, and calming music to support the inward journey.
When evaluating any ketamine clinic, look for clear indicators of medical oversight : physicians or advanced practice providers on-site during sessions, transparent protocols for managing adverse events, continuous vital sign monitoring, and a thorough intake process. Avoid clinics offering same-day treatment without comprehensive evaluation, or those conducting sessions via telemedicine without real-time medical presence.
Integration support to sustain healing
Integration is the process of translating the neuroplasticity opened by ketamine into lasting behavioral and emotional change. Ketamine infusions create a window of heightened neuroplasticity, but durable shifts require deliberate work during that window. Without structured integration, the profound insights or emotional releases experienced during treatment can fade within days, leaving members wondering why the relief did not last.
Neuroplasticity peaks 24–72 hours after a ketamine session. Research on neurogenesis and synaptogenesis shows that this is when the formation of new neurons and the creation of new connections between neurons are most active. During this window, the brain is exceptionally receptive to reinforcement—new habits, reframed beliefs, somatic practices, and relational patterns can take root more easily than they would under normal conditions.
At Nushama’s New City clinic, integration looks like one-on-one sessions with licensed integration coaches or therapists before and after each treatment. These sessions are active, guided explorations of what emerged during the ketamine experience: emotions that surfaced, memories revisited, metaphors or imagery that carried meaning, physical sensations that signaled a shift, or realizations about relationships, identity, or purpose. Integration coaches help members translate these experiences into practical tools—journaling prompts to deepen reflection, somatic practices to regulate the nervous system, communication strategies to repair relationships, or behavioral experiments to test new patterns in daily life.
Weekly group integration circles are included at no additional cost and are available both virtually and in-person. These circles create a space for shared processing, mutual support, and accountability. Healing from treatment-resistant depression, PTSD, or trauma can feel isolating, and the group format reminds members that they are not alone in their struggles or their breakthroughs.
Without integration, insights may feel profound in the moment but fade without a structure to hold them. Members may struggle to connect the experience to their daily challenges, and there is a risk of the medicine becoming just another intervention that provides temporary relief without lasting change. Integration is a foundational component of the treatment process—as discussed in the importance of ketamine integration . This structured support is available locally in New City, so members can build continuity without the added stress of commuting to Manhattan for follow-up care.
FAQs about ketamine therapy in Rockland County
This section covers insurance coverage, location logistics, referral requirements, expected timelines for relief, and safety protocols for ketamine treatment at Nushama’s New City clinic.
Q: Does insurance cover ketamine or Spravato in Rockland County?
A: Spravato is covered by many major insurance plans, including Oxford, UnitedHealthcare, Cigna, Aetna, and Humana. IV ketamine is typically not covered by insurance and costs approximately $4,800 for the initial six-infusion series. Nushama’s care team verifies benefits during the intake process and offers transparent pricing.
Q: Where exactly is Nushama’s Rockland County clinic, and is parking available?
A: The clinic is located at 200 E. Eckerson Road, Suite 280, New City, NY 10956. On-site parking is available, and the space is designed to feel serene and private—not clinical or institutional.
Q: Do I need a referral from a psychiatrist to start treatment?
A: No referral is required. Nushama conducts a comprehensive psychiatric evaluation during the intake process to determine if ketamine or Spravato is appropriate. However, the team welcomes collaboration with your existing therapist or psychiatrist and can coordinate care with your permission.
Q: How quickly can I expect to feel relief?
A: Many members report noticeable improvements within 24–72 hours of the first infusion, though the full benefit typically builds across the acute treatment series (6 infusions over 2–3 weeks for IV ketamine; 8 sessions over 4 weeks for Spravato). Results vary based on symptom severity, treatment history, and engagement with integration support.
Q: What safety measures are in place during the treatment session?
A: Every session includes continuous monitoring by board-certified physicians and ACLS-certified nurses. Vital signs (heart rate, blood pressure, oxygen saturation) are checked every 10 minutes. Integration coaches remain in the room to provide grounding and
